Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union

European Respiratory Journal

Volumn 49, Issue 3, 2017, Pages

  Van Der Werf, Marieke J ^a   Hollo, Vahur ^a   Ködmön, Csaba ^a   Dara, Masoud ^b   Catchpole, Mike ^a  

^a EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; CIPROFLOXACIN; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; OFLOXACIN; PROTIONAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; EUROPEAN UNION; HUMAN; LETTER; LUNG TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; SHORT COURSE THERAPY; DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MYCOBACTERIUM TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; EUROPEAN UNION; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85020219393     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01992-2016     Document Type: Letter

References (15)

1. World Health Organization (WHO). WHO Treatment Guidelines for Drug-resistant Tuberculosis – 2016 Update. Geneva, World Health Organization, 2016.
2. Aung KJ, Van Deun A, Declercq E, et al. Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 2014; 18: 1180–1187.
3. Kuaban C, Noeske J, Rieder HL, et al. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis 2015; 19: 517–524.
4. Piubello A, Harouna SH, Souleymane MB, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014; 18: 1188–1194.
5. Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684–692.
6. European Centre for Disease Prevention and Control, World Health Organization Regional Office for Europe. Tuberculosis Surveillance and Monitoring in Europe, 2016. Stockholm, European Centre for Disease Prevention and Control, 2016.
7. Hewlett D Jr, Horn DL, Alfalla C. Drug-resistant tuberculosis: inconsistent results of pyrazinamide susceptibility testing. JAMA 1995; 273: 916–917.
8. Heifets L. Susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 2002; 51: 11–12.
9. World Health Organization. Policy Guidance on Drug-susceptibility Testing (DST) of Second-line Antituberculosis Drugs. Geneva, World Health Organization, 2008.
10. Jugheli L, Bzekalava N, de Rijk P, et al. High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother 2009; 53: 5064–5068.
11. Willby M, Sikes RD, Malik S, et al. Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2015; 59: 5427–5434.
12. Sotgiu G, Tiberi S, D’Ambrosio L, et al. WHO recommendations on shorter treatment of multidrug-resistant tuberculosis. Lancet 2016; 387: 2486–2487.
13. Sotgiu G, Tiberi S, D’Ambrosio L, et al. Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis. Eur Respir J 2016; 48: 1503–1507.
14. Moodley R, Godec TR, STREAM Trial Team. Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials. Eur Respir Rev 2016; 25: 29–35.
15. Wallis RS, Maeurer M, Mwaba P, et al. Tuberculosis – advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infect Dis 2016; 16: e34–e46.